Skip to the content
REVOLUTIONIZING TREATMENT DECISIONS
Follow us on
Home
Solutions
INNOVATIVE TRIAL DESIGN
Inform Strategic Decisions
Benefit-Risk Assessment
Resources
Net Treatment Benefit
Press Releases
Regulatory submissions
Blogs
Case studies
Peer-reviewed papers
About
About One2Treat
One2Treat’s Team
Contact
Careers
Request a demo
Home
Solutions
INNOVATIVE TRIAL DESIGN
Inform Strategic Decisions
Benefit-Risk Assessment
Resources
Net Treatment Benefit
Press Releases
Regulatory submissions
Blogs
Case studies
Peer-reviewed papers
About
About One2Treat
One2Treat’s Team
Contact
Careers
FDA
▶
Regulatory submissions
A Study of Retatrutide in Participants Who Have Obesity or Overweight (2023)
Back
Click on the image below to view this study.
Read also
FDA
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (2019)
READ MORE
→
FDA
Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery (2023)
READ MORE
→
FDA
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy (2019)
READ MORE
→
FDA
CardiAMP™ Cell Therapy for Heart Failure Trial (2016)
READ MORE
→
Want to invest in a more holistic understanding
of net treatment benefit?
Get in touch